Trial · NCT01623167
Adverse events489
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 489
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | hATG, CsA, EPAG Day 14 to Month 6 | 2 | 30 | 2 |
| other | Abdominal pain | Gastrointestinal disorders | hATG, CsA, EPAG Day 14 to Month 3 | 1 | 31 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | hATG, CsA (Dose Reduced), EPAG Day 1 to Month 6 | 1 | 31 | 1 |
| other | Acute kidney injury | Renal and urinary disorders | hATG, CsA, EPAG Day 14 to Month 6 | 0 | 30 | 0 |
| other | Acute kidney injury | Renal and urinary disorders | hATG, CsA, EPAG Day 14 to Month 3 | 1 | 31 | 1 |
| other | Acute kidney injury | Renal and urinary disorders | hATG, CsA (Dose Reduced), EPAG Day 1 to Month 6 | 0 | 31 | 0 |
| other | Alanine aminotransferase increased | Investigations | hATG, CsA, EPAG Day 14 to Month 6 | 3 | 30 | 3 |
| other | Alanine aminotransferase increased | Investigations | hATG, CsA, EPAG Day 14 to Month 3 | 8 | 31 | 17 |
| other | Alanine aminotransferase increased | Investigations | hATG, CsA (Dose Reduced), EPAG Day 1 to Month 6 | 11 | 31 | 17 |
| other | Alanine aminotransferase increased (intermittent) | Investigations | hATG, CsA, EPAG Day 14 to Month 6 | 0 | 30 | 0 |
| other | Alanine aminotransferase increased (intermittent) | Investigations | hATG, CsA, EPAG Day 14 to Month 3 | 1 | 31 | 1 |
| other | Alanine aminotransferase increased (intermittent) | Investigations | hATG, CsA (Dose Reduced), EPAG Day 1 to Month 6 | 0 | 31 | 0 |
| other | Allergic reaction | Immune system disorders | hATG, CsA, EPAG Day 14 to Month 6 | 1 | 30 | 1 |
| other | Allergic reaction | Immune system disorders | hATG, CsA, EPAG Day 14 to Month 3 | 0 | 31 | 0 |
| other | Allergic reaction | Immune system disorders | hATG, CsA (Dose Reduced), EPAG Day 1 to Month 6 | 0 | 31 | 0 |
| other | Aspartate aminotransferase increased | Investigations | hATG, CsA, EPAG Day 14 to Month 6 | 2 | 30 | 2 |
| other | Aspartate aminotransferase increased | Investigations | hATG, CsA, EPAG Day 14 to Month 3 | 3 | 31 | 4 |
| other | Aspartate aminotransferase increased | Investigations | hATG, CsA (Dose Reduced), EPAG Day 1 to Month 6 | 7 | 31 | 8 |
| other | Atrial fibrillation | Cardiac disorders | hATG, CsA, EPAG Day 14 to Month 6 | 1 | 30 | 1 |
| other | Atrial fibrillation | Cardiac disorders | hATG, CsA, EPAG Day 14 to Month 3 | 0 | 31 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01623167/events